Agents with vasodilator properties in acute heart failure

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Acute heart failure (AHF) affects millions globally, presenting significant short-term and intermediate-term management challenges.
• Current intravenous therapies for AHF, primarily vasodilators, lack robust evidence for improving long-term clinical outcomes beyond symptom relief.
• Existing treatments like nitrates, nitroprusside, and nesiritide show limited efficacy in preventing end-organ dysfunction or reducing hospital readmissions.

Purpose of the Study:

• To review novel vasodilating agents under development for acute heart failure treatment.
• To highlight the urgent need for therapies that improve both in-hospital and post-discharge outcomes in AHF.
• To assess the potential of emerging drug classes in addressing unmet needs in AHF management.

Main Methods:

• Review of recently developed novel agents with vasodilating properties for AHF.
• Categorization of agents based on their mechanism of action, including natriuretic peptides, nitroxyl donors, and soluble guanylate cyclase modulators.
• Overview of the developmental stages of these novel agents, from early studies to large mortality trials.

Main Results:

• Several novel vasodilating agents are in various stages of clinical development for AHF.
• These agents include serelaxin, ularitide, cenderitide, TRV120027, CXL-1020, CXL-1427, cinaciguat, vericiguat, clevidipine, and nicorandil.
• Development programs range from early dose-finding studies to large multicenter mortality trials.

Conclusions:

• There is a critical need for effective vasodilating therapies to improve clinical outcomes in AHF.
• Novel agents targeting different pathways show promise for improving both acute symptoms and long-term prognosis.
• These emerging treatments represent potential opportunities to address the limitations of current AHF management strategies.